ArticleLancet regional health. Americas2025
Prevalence of HPV, cytological abnormalities, and impact of the HPV vaccine in Mexico: a Nationwide Study of 596,944 women.
Article in Lancet regional health. Americas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mapping the global research landscape on HPV vaccine hesitancy: a machine-learning based bibliometric analysis.Virology journal · 2026Article
- Towards HPV elimination: closing the gender gap by vaccinating and screening men.Lancet regional health. Americas · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cervical cancer (CC) remains a significant public health challenge worldwide and is the second leading cause of cancer-related death in women in Mexico. Although CC is highly preventable, effective implementation of screening programs to detect women with precancerous lesions is crucial to reduce its burden. This study evaluated HPV infection, its correlation with cytological abnormalities, and the impact of HPV vaccination in 596,944 women from all 32 states of Mexico. Methods: Samples were processed using a fully automated molecular biology laboratory setup (Roche Cobas prime - Cobas 6800), and cytotechnologists assessed cytological outcomes. Findings: The highest prevalence of HPV infection was observed among women under the age of 25, with 23,615 individuals (37.4%) testing positive. This was primarily attributable to infections with the pooled high-risk HPV genotypes included in the assay (HPV31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), which accounted for 22,792 cases (36.1%). In contrast, HPV16 and HPV18 were most prevalent among women aged 25-34 years, with 7251 (5.21%) and 3281 (2.36%) infections, respectively. Low-grade squamous intraepithelial lesion (LSIL) was the most frequently detected cytological abnormality, identified in 15,411 cases (2.6%), and was predominantly associated with the pooled HPV genotypes (73.7%). A two-dose HPV vaccination regimen conferred strong protection against HPV16 (odds ratio [OR] = 0.21) and HPV18 (OR = 0.33), but did not significantly reduce the prevalence of infection with the pooled HPV genotypes (OR = 0.98). Interpretation: The notable carcinogenic potential of the HPV POOL underscores the need for broader vaccine formulations. Adopting a nonavalent vaccine in future campaigns, expanding screening coverage, and reinforcing sexual education for younger women are key measures to help policymakers mitigate the impact of CC in Mexico. Funding: This work was funded by Salud Digna.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.